<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2021.791017</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gunther</surname>
<given-names>Randall C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bharathi</surname>
<given-names>Vanthana</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miles</surname>
<given-names>Stephen D.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tumey</surname>
<given-names>Lauryn R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schmedes</surname>
<given-names>Clare M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tatsumi</surname>
<given-names>Kohei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1534945"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bridges</surname>
<given-names>Meagan D.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1535035"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Montgomery</surname>
<given-names>Stephanie A.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beck</surname>
<given-names>Melinda A.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/975845"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Camerer</surname>
<given-names>Eric</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/838346"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mackman</surname>
<given-names>Nigel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Antoniak</surname>
<given-names>Silvio</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/156044"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>UNC Blood Research Center, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>UNC Lineberger Comprehensive Cancer Center, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Nutrition, Gillings School of Global Public Health, School of Medicine, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Medicine, Universit&#xe9; de Paris, Paris Cardiovascular Research Center (PARCC), INSERM UMR 970</institution>, <addr-line>Paris</addr-line>, <country>France</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>UNC Blood Research Center, UNC Lineberger Comprehensive Cancer Center, UNC McAllister Heart Institute, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Chaofeng Han, Second Military Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Bin Gong, University of Texas Medical Branch at Galveston, United States; Takehiko Shibata, Tokyo Medical University, Japan</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Silvio Antoniak, <email xlink:href="mailto:antoniak@email.unc.edu">antoniak@email.unc.edu</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>791017</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>10</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Gunther, Bharathi, Miles, Tumey, Schmedes, Tatsumi, Bridges, Martinez, Montgomery, Beck, Camerer, Mackman and Antoniak</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Gunther, Bharathi, Miles, Tumey, Schmedes, Tatsumi, Bridges, Martinez, Montgomery, Beck, Camerer, Mackman and Antoniak</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Innate immune responses to influenza A virus (IAV) infection are initiated in part by toll-like receptor 3 (TLR3). TLR3-dependent signaling induces an antiviral immune response and an NF&#x3ba;B-dependent inflammatory response. Protease-activated receptor 2 (PAR2) inhibits the antiviral response and enhances the inflammatory response. PAR2 deficiency protected mice during IAV infection. However, the PAR2 expressing cell-types contributing to IAV pathology in mice and the mechanism by which PAR2 contributes to IAV infection is unknown.</p>
</sec>
<sec>
<title>Methods</title>
<p>IAV infection was analyzed in global (<italic>Par2<sup>-/-</sup>
</italic>), myeloid (<italic>Par2</italic>
<sup>fl/fl</sup>;LysM<sup>Cre+</sup>) and lung epithelial cell (EpC) <italic>Par2</italic> deficient (<italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup>) mice and their respective controls (<italic>Par2</italic>
<sup>+/+</sup> and <italic>Par2</italic>
<sup>fl/fl</sup>). In addition, the effect of PAR2 activation on polyinosinic-polycytidylic acid (poly I:C) activation of TLR3 was analyzed in bone marrow-derived macrophages (BMDM). Lastly, we determined the effect of PAR2 inhibition in wild-type (WT) mice.</p>
</sec>
<sec>
<title>Results</title>
<p>After IAV infection, <italic>Par2<sup>-/-</sup>
</italic> and mice with myeloid <italic>Par2</italic> deficiency exhibited increased survival compared to infected controls. The improved survival was associated with reduced proinflammatory mediators and reduced cellular infiltration in bronchoalveolar lavage fluid (BALF) of <italic>Par2<sup>-/-</sup>
</italic> and <italic>Par2</italic>
<sup>fl/fl</sup>;LysM<sup>Cre+</sup> 3 days post infection (dpi) compared to infected control mice. Interestingly, <italic>Par2</italic>
<sup>fl/fl</sup>;SPC<sup>Cre+</sup> mice showed no survival benefit compared to <italic>Par2<sup>fl/fl</sup>
</italic>. <italic>In vitro</italic> studies showed that <italic>Par2<sup>-/-</sup>
</italic> BMDM produced less IL6 and IL12p40 than <italic>Par2</italic>
<sup>+/+</sup> BMDM after poly I:C stimulation. In addition, activation of PAR2 on <italic>Par2</italic>
<sup>+/+</sup> BMDM increased poly I:C induction of IL6 and IL12p40 compared to poly I:C stimulation alone. Importantly, PAR2 inhibition prior to IAV infection protect WT mice.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Global <italic>Par2</italic> or myeloid cell but not lung EpC <italic>Par2</italic> deficiency was associated with reduced BALF inflammatory markers and reduced IAV-induced mortality. Our study suggests that PAR2 may be a therapeutic target to reduce IAV pathology.</p>
</sec>
</abstract>
<kwd-group>
<kwd>toll-like receptor 3</kwd>
<kwd>influenza A virus</kwd>
<kwd>innate immune response</kwd>
<kwd>macrophage</kwd>
<kwd>lung epithelial cell</kwd>
<kwd>protease-activated receptor 2 (PAR2)</kwd>
<kwd>F2rl1</kwd>
</kwd-group>
<contract-num rid="cn001">1R35HL155657, 1R01HL142799</contract-num>
<contract-sponsor id="cn001">NHLBI Division of Intramural Research<named-content content-type="fundref-id">10.13039/100017540</named-content>
</contract-sponsor>
<counts>
<fig-count count="12"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="81"/>
<page-count count="15"/>
<word-count count="6393"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Influenza is a group of single-stranded RNA (ssRNA) viruses within the Orthomyxoviridae family which are responsible for over 5 million hospitalizations per year globally, occurring in young children (under the age of 2 years) and adults at the highest rates in those &#x2265;65 years (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). In particular, influenza A virus (IAV) is known for its ability to cause pandemics in the context of genetic shift, and as the long-standing major viral etiology of acute respiratory distress syndrome (ARDS) in adults (<xref ref-type="bibr" rid="B3">3</xref>). The ongoing coronavirus pandemic has highlighted the importance of studying the pathophysiological mechanisms underlying the course of illness and complications associated with severe respiratory viral infections.</p>
<p>The pathophysiology of lung inflammation and damage during influenza virus infection can be attributed to 1/virus-mediated and 2/host immune response-mediated mechanisms, with the latter including features of the innate immune response, such as neutrophil infiltration and pro-inflammatory mediator production (<xref ref-type="bibr" rid="B3">3</xref>). Toll-like receptors (TLRs) initiate innate immune responses by recognizing pathogen associated molecular patterns (PAMPs) (<xref ref-type="bibr" rid="B4">4</xref>). Double-stranded RNA (dsRNA) is a major viral PAMP generated during replication of ssRNA viruses (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). TLR3 recognition of dsRNA leads to the activation of two pathways: 1/the anti-viral type-I interferon (IFN) response and 2/the NF&#x3ba;B pro-inflammatory response (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Importantly, TLR3 is a critical regulator of the innate immune response to IAV (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B9">9</xref>). TLR3 deficiency was associated with reduced IAV-associated lung inflammation and mortality (<xref ref-type="bibr" rid="B9">9</xref>). Within the lung, IAV replicates primarily in epithelial cells (EpCs) and leads to damage of the EpC layer which reduces gas exchange (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). However, there is evidence that replication may occur at lower levels within all cell types found in the murine lung, including alveolar macrophages (AM&#x3a6;) (<xref ref-type="bibr" rid="B11">11</xref>). Importantly, EpCs and AM&#x3a6; are among the first cells to response to pathogens in the lung, including IAV (<xref ref-type="bibr" rid="B12">12</xref>). AM&#x3a6; are one of the major sources of type-I IFN after respiratory RNA virus infections (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Moreover, AM&#x3a6; are essential in protecting against IAV infection (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). However, excessive AM&#x3a6; activation contributes to IAV pathology by releasing proapoptotic factors causing direct EpC injury/death (<xref ref-type="bibr" rid="B17">17</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>Protease activated receptors (PARs) are a group of four G-protein coupled receptors (PAR1-4) which are expressed broadly in humans and mice (<xref ref-type="bibr" rid="B20">20</xref>). For instance, PAR2 is expressed on nucleated circulating blood cells and within all organs, including the lung (<xref ref-type="bibr" rid="B20">20</xref>). In the lung, PAR2 is present on the surface of AM&#x3a6; and EpCs, and expression is upregulated in response to IAV (<xref ref-type="bibr" rid="B21">21</xref>). It was proposed that TLRs and PARs act together to detect PAMPs and infection-associated changes in protease gradients within the extracellular milieu, respectively (<xref ref-type="bibr" rid="B22">22</xref>). Nhu et&#xa0;al. (<xref ref-type="bibr" rid="B23">23</xref>) showed that PAR2 stimulation increased TLR3:NF&#x3ba;B inflammation but suppressed TLR3:type-I IFN anti-viral responses in human EpC lines <italic>in vitro</italic>. In addition, the authors showed that <italic>Par2</italic> deficiency was associated with reduced IAV-induced mortality (<xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>Here, we investigate the PAR2-dependent early immune responses to IAV infection in mice. In addition, using mice with a cell-specific <italic>Par2</italic> deficiency, we investigated the contribution of EpC and myeloid cell expressed PAR2 to IAV-induced lung pathology. Lastly, we determined if PAR2 inhibition in wild-type (WT) mice can be a therapeutic approach to reduce IAV infection.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>Mice</title>
<p>Female and male mice between 8-12 weeks of age were used in this study. <italic>Par2</italic> (<italic>F2lr1</italic>) knockout (<italic>Par2<sup>&#x2010;/&#x2010;</sup>
</italic>) and their respective control (<italic>Par2<sup>+/+</sup>
</italic>) mice, maintained as cousin lines, were used for this study (<xref ref-type="bibr" rid="B24">24</xref>). Mice carrying floxed Par2 alleles (<italic>Par2<sup>fl/fl</sup>
</italic>, targeted allele name: <italic>F2rl1</italic>
<sup>tm1a(EUCOMM)Wtsi</sup>) were generated using C57Bl/6 ES cells from EUCOMM as described (<xref ref-type="bibr" rid="B25">25</xref>). Additional information about the <italic>Par2<sup>fl/fl</sup>
</italic> mice is available at <uri xlink:href="http://www.informatics.jax.org/allele/MGI:4460480">http://www.informatics.jax.org/allele/MGI:4460480</uri>. Cell-specific PAR2 deficient mice were generated by crossing female <italic>Par2<sup>fl/fl</sup>
</italic> with male <italic>Par2<sup>fl/fl</sup>
</italic> mice expressing Cre recombinase in a cell type&#x2010;specific manner. To generate mice with <italic>Par2</italic> deleted in lung EpCs we used the surfactant protein C (SPC) promoter (<italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup> mice) (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). The <italic>Par2</italic> gene was deleted in the myeloid lineage (monocytes/macrophages and neutrophils) using the lysosomal M (LysM) promoter (<italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup>) (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>&#x2013;<xref ref-type="bibr" rid="B31">31</xref>). For mice with cell type-specific <italic>Par2</italic> deletion, littermate <italic>Par2<sup>fl/fl</sup>
</italic> mice were used as controls. All mouse strains were on the C57Bl/6 background. The study was approved and performed in accordance with the guidelines of the animal care and use committee of the University of North Carolina at Chapel Hill and complies with National Institutes of Health guidelines.</p>
</sec>
<sec id="s2_2">
<title>IAV Infection</title>
<p>Mouse-adapted influenza A/Puerto Rico/8/1934 (PR8) virus strain was propagated in 10-12 day old embryonated chicken eggs and titers were quantified by hemagglutination unit (HAU) assay (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Mice were inoculated with 0.04 HAU in 50 &#xb5;l PBS administered intranasally (i.n.) as previously described (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). This dose results in a ~40% mortality in WT mice. Mice were given free access to feed and water while being monitored over the course of infection. Changes in body weights were recorded daily and mice were euthanized if they had &#x2265; 25% loss of initial body weight, as specified in our animal protocol.</p>
</sec>
<sec id="s2_3">
<title>
<italic>In Vivo</italic> PAR2 Inhibition</title>
<p>Eight-week old male C57BL/6J mice purchased from Jackson Laboratories (Bar Harbor, ME) were used for PAR2 inhibition studies. Thirty minutes prior to IAV infection, mice were administered i.n. 20 ng anti-mouse PAR2 antibody (SAM11, Santa Cruz Biotechnology, Dallas, TX) or IgG<sub>2a</sub> control antibody (clone C1.18.4, Millipore Sigma, Burlington, MA) in 25 &#xb5;l sterile normal saline to isoflurane anesthetized mice (<xref ref-type="bibr" rid="B34">34</xref>). Subsequently, 0.04 HAU IAV in 25 &#xb5;l PBS was administered i.n. as described above. At 24 and 48 hours post-infection, mice were administered i.n. additional 20 ng and 2 &#xb5;g, respectively, of SAM11 or IgG<sub>2a</sub> control in 50 &#xb5;l sterile normal saline.</p>
</sec>
<sec id="s2_4">
<title>Bronchoalveolar Lavage Fluid Collection and Analysis</title>
<p>Mice were anesthetized with isoflurane and venous blood was collected from the inferior vena cava after injection of 0.2 mL sodium citrate. Mice were subsequently euthanized by cervical dislocation and bronchoalveolar lavage fluid (BALF) was collected with 3 x 900 &#xb5;L ice&#x2010;cold PBS as described previously (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). BALF samples were centrifugated and the cell free supernatant was collected (<xref ref-type="bibr" rid="B33">33</xref>). Cell pellets were resuspended in 200 &#xb5;L PBS, and total white blood cell (WBC), neutrophil, and lymphocyte numbers were determined with an Element HT5 veterinary hematology analyzer (Heska, Loveland, CO) (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Lung tissue was resected, snap frozen in liquid nitrogen and stored at -80&#xb0;C for further analysis. A limitation of automated cell counting for BALF cellularity is that the automated systems tends to underestimate the amount of monocytes/macrophages, especially AM&#x3a6;, in BALF preparations and potentially misrecognizes them as eosinophils (<xref ref-type="bibr" rid="B35">35</xref>).</p>
</sec>
<sec id="s2_5">
<title>Real&#x2010;Time Polymerase Chain Reaction</title>
<p>Total RNA was isolated from snap frozen untreated lung or lung from lavage experiments, using the TRIzol method (Thermo Fisher Scientific) (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). One microgram of total RNA was transcribed to complementary DNA (iScript RT Supermix Kit, Bio&#x2010;Rad Laboratories, Hercules, CA). Levels of IAV genomic RNA and IFN&#x3b2; mRNA were analyzed by real&#x2010;time PCR using SSoFast Advanced Universal Supermix in a Bio&#x2010;Rad cycler (Bio&#x2010;Rad Laboratories) as described elsewhere (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Predesigned primer&#x2010;probe sets for H1N1 IAV genomic RNA and mouse IFNB1 (IFN&#x3b2;) were obtained from Integrated DNA Technologies (Coralville, IA) (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B36">36</xref>).</p>
</sec>
<sec id="s2_6">
<title>Lung Histopathology and Disease Scoring</title>
<p>To obtain lung tissue for histology, a subset of mice were anesthetized with isoflurane and were perfused with 2.5 mL 10U/mL heparin in PBS <italic>via</italic> injection into the right ventricle of the heart 7dpi as described (<xref ref-type="bibr" rid="B37">37</xref>). Mice were euthanized, and lungs were insufflated gently with 0.6 mL 10% phosphate-buffered formalin (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Lungs were removed and were fixed in 10% phosphate-buffered formalin, paraffin embedded, and sectioned at 4 &#x3bc;m. Sections (maximal airspace) of the left lung were stained with hematoxylin and eosin (H&amp;E) (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Sections taken from similar anatomic location and were compared by a blinded pathologist for signs of lung EpC injury with focus on EpC layer disorganization, EpC layer thinning/stretching and total loss of EpC layer within the medium sized airways.</p>
</sec>
<sec id="s2_7">
<title>Non-Invasive Lung Function Measurement</title>
<p>Global lung function was recorded on conscious mice using a Buxco whole-body plethysmography system (Data Science International, New Brighton, MN) 7dpi to quantify Penh, a measure of calculated airway resistance, EF<sub>50</sub>, midbreath expiratory flow, and Rpef, the rate of peak expiratory flow (<xref ref-type="bibr" rid="B39">39</xref>). Briefly, <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>&#x2010;/&#x2010;</sup>
</italic> mice were placed into individual chambers and allowed to acclimate for 20 min before a 30 min measurement window. Continuous 2-second summaries were recorded and averaged every 1 min for a total of 30 measurements per mouse (<xref ref-type="bibr" rid="B39">39</xref>).</p>
</sec>
<sec id="s2_8">
<title>Bone Marrow-Derived Macrophages</title>
<p>Eight-week old male <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>&#x2010;/&#x2010;</sup>
</italic> mice were sacrificed by isoflurane overdose with additional cervical dislocation and femurs were excised and cleaned. Medullary cavities were flushed with ice-cold PBS and the resulting suspension was filtered through a 40-micron filter. Cells were resuspended and incubated at 37&#xb0;C on 10cm cell culture petri dishes for three hours. Non-adherent cells were collected and plated on 10cm cell culture treated petri dishes at a concentration of 3 x 10<sup>5</sup> cells/mL in Iscove&#x2019;s Modified Dulbecco&#x2019;s Media supplemented with 10% FBS (Omega Scientific, Tarzana, CA), 1% Penicillin-Streptomycin (Sigma-Aldrich, St. Louis, MO), and 50 ng/mL M-CSF (R&amp;D Systems) with media exchange every three days. On day 7, the bone marrow-derived macrophages (BMDM) were dissociated by Trypsin-EDTA (Sigma-Aldrich) for 3 minutes and gently scraped from the plate. BMDM were seeded on 24 well or 12 well cell culture treated plates at a concentration of 2x10<sup>5</sup> cells/mL in DMEM/F12 supplemented with 10% FBS, 100 mM L-glutamine, and 1% Penicillin-Streptomycin 36 hours prior to stimulation. Media was exchanged and BMDM were stimulated with 5 &#xb5;g/mL polyinosinic-polycytidylic acid (poly I:C, Tocris, Minneapolis, MN) and/or 200 &#xb5;M PAR2 agonist peptide (PAR2 AP, SLIGRL&#x2010;NH<sub>2</sub>, R&amp;D Systems).</p>
</sec>
<sec id="s2_9">
<title>ELISA</title>
<p>Protein levels of TNF&#x3b1;, MCP1, CXCL1, IL1&#x3b2;, IL6, and IL12p40 in BALF and BMDM conditioned media was analyzed by ELISA (Duo-Set, R&amp;D Systems, Minneapolis, MN) (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B40">40</xref>).</p>
</sec>
<sec id="s2_10">
<title>Statistics</title>
<p>GraphPad Prism 9.2 (GraphPad Software Inc, San Diego, CA) was used for statistical analysis. Data are represented as mean &#xb1; standard error of the mean (SEM). The two&#x2010;tailed Student <italic>t</italic> test was used for two&#x2010;group comparison of normally distributed data. For multiple&#x2010;group comparison, normally distributed data were analyzed by two&#x2010;way ANOVA test and were Bonferroni&#x2010;corrected for repeated measure over time. Survival rates were analyzed by Kaplan&#x2013;Meier analysis and the log&#x2010;rank test was applied to compare the survival distribution between the two groups. <italic>P</italic> value &#x2264; 0.05 was regarded as significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>
<italic>Par2</italic> Deficiency Is Associated With Reduced IAV-Induced Mortality</title>
<p>Mice were monitored daily for 14 days for weight loss following IAV infection. Weight loss &#x2265;25% or actual death were criteria for mortality. Body weight curves were constructed showing daily weights of mice remaining that had not met mortality criteria. (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). After infection, mice of both genotypes exhibited similar body weight changes up to 7 days post infection (dpi) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). However, <italic>Par2<sup>-/-</sup>
</italic> mice exhibited improved body weight recovery compared to <italic>Par2<sup>+/+</sup>
</italic> mice starting 8dpi. The calculated Kaplan Meier survival curves constructed for mice over the course of the infection showed that <italic>Par2<sup>-/-</sup>
</italic> mice had significantly improved survival compared to infected <italic>Par2</italic>
<sup>+/+</sup> mice 14dpi (P&lt;0.05) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>PAR2 deficiency is associated with improved survival after IAV infection. <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were infected with 0.04 HAU IAV and changes in body weights were recorded daily for 14 days <bold>(A)</bold>. Overall survival <bold>(B)</bold> was observed as well as calculated from body weights for 14 days. A weight loss of &#x2265;25% of the initial body weight was set as compassionate humane endpoint as specified in the animal protocol. Body weights before infection (day 0) was set to 100%. Data (mean &#xb1; SEM) and calculated survival were analyzed by two-way ANOVA <bold>(A)</bold> and log-rank test <bold>(B)</bold>. *P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g001.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>PAR2 Regulates Cytokine and Neutrophil Accumulation in the Airspace After AV Infection</title>
<p>Severe IAV infection provokes monocyte/macrophage and neutrophil infiltration that can drive IAV-induced pathology (<xref ref-type="bibr" rid="B17">17</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>). Importantly, neutrophils have been implicated in a feed-forward pathogenic program in IAV infection (<xref ref-type="bibr" rid="B41">41</xref>). To evaluate the role of PAR2 in early inflammatory responses in the airspace after IAV infection, BALF of <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice was collected 3dpi and assayed for proinflammatory cytokines/chemokines and infiltrating immune cell numbers. As expected, <italic>Par2<sup>-/-</sup>
</italic> mice had significantly reduced levels of a subset of proinflammatory mediators, including TNF&#x3b1;, MCP1, CXCL1, IL1&#x3b2;, IL6, and IL12p40 compared to <italic>Par2<sup>+/+</sup>
</italic> mice (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A&#x2013;F</bold>
</xref>). Moreover, decreased total white blood cell, neutrophil and monocyte numbers were observed in BALF of <italic>Par2<sup>-/-</sup>
</italic> mice compared to BALF of <italic>Par2</italic>
<sup>+/+</sup> mice at 3dpi (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A&#x2013;C</bold>
</xref>). There were no significant differences detected in levels of lymphocytes in the BALF of the two genotypes at 3dpi (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>). In addition, <italic>Par2</italic>
<sup>-/-</sup> BALF exhibited reduced eosinophil numbers compared to <italic>Par2</italic>
<sup>+/+</sup> mice BALF at 3dpi (<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplement Figure&#xa0;1</bold>
</xref>). Some of these cells may be AM&#x3a6; because the automated cell counter cannot easily distinguish these cell types (<xref ref-type="bibr" rid="B35">35</xref>). However, at 7dpi there were, with exception for IL6, similar BALF inflammatory mediator levels in the two genotypes (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplement Figure&#xa0;2</bold>
</xref>). Importantly, while TNF&#x3b1;, MCP1, CXCL1 and IL12p40 BALF levels were no longer different between the two genotypes at 7dpi, BALF of <italic>Par2</italic>
<sup>+/+</sup> mice still exhibited increased cellularity with significantly higher total WBC, neutrophil, and monocyte numbers compared to <italic>Par2<sup>-/-</sup>
</italic> mice BALF 7dpi (<xref ref-type="supplementary-material" rid="SF3">
<bold>Supplement Figure&#xa0;3</bold>
</xref>). Moreover, lymphocytes and eosinophils numbers in BALF were similar between the two genotypes at 7dpi (<xref ref-type="supplementary-material" rid="SF3">
<bold>Supplement Figure&#xa0;3</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>PAR2 deficiency results in reduced inflammation in the airspace after IAV infection. <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were infected with 0.04 HAU IAV and bronchoalveolar lavage fluid (BALF) was analyzed for TNF&#x3b1; <bold>(A)</bold>, MCP1 <bold>(B)</bold>, CXCL1 <bold>(C)</bold>, IL1&#x3b2; <bold>(D)</bold>, IL6 <bold>(E)</bold> and IL12p40 <bold>(F)</bold> protein levels 3 days after infection by ELISA. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.005, ****P &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>PAR2 deficiency results in reduced cellular inflammation in the airspace after IAV infection. <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were infected with 0.04 HAU IAV and bronchoalveolar lavage fluid (BALF) cellularity was analyzed by automated cell counter for total white blood cell (WBC) <bold>(A)</bold>, neutrophil <bold>(B)</bold>, monocytes <bold>(C)</bold> and lymphocyte <bold>(D)</bold> numbers 3 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>
<italic>Par2</italic> Deficiency Is Associated Increased IFN&#x3b2; Expression and Reduced IAV Genome Levels in the Lung</title>
<p>Type-I IFN signaling was shown to restrict IAV replication and pathologic inflammatory immune responses in the IAV infected lung (<xref ref-type="bibr" rid="B42">42</xref>). We and others showed that <italic>Par2</italic> deficiency was associated with increased IFN&#x3b2; expression <italic>in vivo</italic> and <italic>in vitro</italic> (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B43">43</xref>). In addition, we linked PAR2 expression and activation to increased Coxsackievirus B3 replication <italic>in vitro</italic> (<xref ref-type="bibr" rid="B43">43</xref>). To analyze the effect of PAR2 expression on antiviral IFN&#x3b2; expression and IAV replication in infected lungs, RNA was isolated and IFN&#x3b2; mRNA as well as IAV genomes measured in lungs of <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice 3dpi. Importantly, infected <italic>Par2<sup>-/-</sup>
</italic> mice lungs exhibited increased IFN&#x3b2; mRNA expression compared to infected <italic>Par2<sup>+/+</sup>
</italic> mice lungs 3dpi (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). In line with increased antiviral response, <italic>Par2</italic> deficiency was associated with reduced IAV genome levels in the lung compared to <italic>Par2<sup>+/+</sup>
</italic> mice lungs 3dpi (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>PAR2 deficiency results in IFN&#x3b2; expression and reduced virus load in the lung after IAV infection. <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were infected with 0.04 HAU IAV and IFN&#x3b2; mRNA expression <bold>(A)</bold> and IAV genomes <bold>(B)</bold> in the lungs were analyzed by RT-PCR 3 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g004.tif"/>
</fig>
</sec>
<sec id="s3_4">
<title>PAR2 Contributes to Lung Epithelial Cell Loss During IAV Infection</title>
<p>IAV primarily infects and replicates in lung epithelium which results in loss of alveolar and bronchial EpCs up to 7dpi. Repair of the EpC layer begins after day 7 when surviving mice start regaining body weight (<xref ref-type="bibr" rid="B44">44</xref>). Importantly, loss of more than 10% of alveolar EpCs is correlated with increased mortality in IAV-infected mice (<xref ref-type="bibr" rid="B45">45</xref>). To analyze IAV-induced lung EpC injury formalin-fixed and paraffin-embedded lung sections of IAV-infected <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice (7dpi) were cut to maximal airspace and stained with H&amp;E. The most striking difference between <italic>Par2<sup>+/+</sup>
</italic> (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>) and <italic>Par2<sup>-/-</sup>
</italic> (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>) mice was that infected <italic>Par2<sup>+/+</sup>
</italic> mice exhibited more signs of lung EpC injury compared with <italic>Par2<sup>-/-</sup>
</italic> mice. This included more severe disorganized lung EpC layer (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A1</bold>
</xref>) indicating concurrent cell damage and regeneration, EpC stretching/thinning (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A2</bold>
</xref>) and total EpC loss (denudation, <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A3</bold>
</xref>), accumulation of neutrophils and cellular debris in the airway lumen compared to infected <italic>Par2<sup>-/-</sup>
</italic> mice (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>) which showed only infection-induced disorganization of the EpC layer (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B1</bold>
</xref>). The obvious changes in the lung epithelial histology suggest that PAR2-dependent inflammation during IAV infection leads to more pronounced lung EpC injury which may explain the delayed body weight recovery and the increased mortality in <italic>Par2<sup>+/+</sup>
</italic> mice as shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>PAR2 expression is associated with increased lung epithelial cell injury after IAV infection. <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were infected with 0.04 HAU IAV and lung sections were cut for maximal airspace and stained with H&amp;E staining 7 days after infection. <bold>(A)</bold> Representative overview of a section of the main left bronchi (maximal airspace) of an IAV-infected <italic>Par2<sup>+/+</sup>
</italic> mouse. Overall, <italic>Par2<sup>+/+</sup>
</italic> mice exhibited more signs of lung epithelial cell injury including disorganization of the epithelial cell layer (<bold>A1</bold>, arrows), epithelial cell thinning/stretching (<bold>A2</bold>, asterisks) and total loss of epithelial cells/denudation (<bold>A3</bold>, arrow heads). Representative overview of a section of the main left bronchi of an IAV-infected <italic>Par2<sup>-/-</sup>
</italic> mouse <bold>(B)</bold> shows a less severe lung epithelial cell injury phenotype with apparent signs of epithelial cell disorganization <bold>(B1</bold>, arrows). Size bar=1mm <bold>(A, B)</bold> and size bar=200&#xb5;m <bold>(A1&#x2013;A3, B1)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g005.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>
<italic>Par2</italic> Deficiency Is Associated With Improved Lung Function After IAV Infection</title>
<p>IAV infection-associated pathology results in impaired lung function with increased airways resistance, increased exhalation force and reduced peak exhalation flow (<xref ref-type="bibr" rid="B39">39</xref>). To measure the global lung function, <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice (7dpi) subjected to Buxco whole-body plethysmography system (<xref ref-type="bibr" rid="B39">39</xref>). Enhanced pause (Penh) is a calculated measure of airway resistance that is associated with airway denudation, airway debris and immune cell accumulation in the airway following IAV infection (<xref ref-type="bibr" rid="B39">39</xref>). The 50% exhalation force (EF<sub>50</sub>) measures the exhalation force midbreath, which increases as breathing becomes more difficult. Finally, the ratio of peak expiratory flow (Rpef) is the time to peak expiratory flow and has been associated with wheezing following infection (<xref ref-type="bibr" rid="B39">39</xref>). All three metrics have been shown to change significantly following IAV infection, with Penh and EF<sub>50</sub> increasing following infection and Rpef decreasing (<xref ref-type="bibr" rid="B39">39</xref>). In line with our findings, <italic>Par2<sup>+/+</sup>
</italic> mice exhibited increased Penh (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>), increased EF<sub>50</sub> (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>) but reduced Rpef (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>) compared to <italic>Par2<sup>-/-</sup>
</italic> mice 7dpi. Combined, these measurements show that <italic>Par2</italic> deficiency was associated with improved lung function after IAV infection.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>PAR2 deficiency was associated with less severe lung dysfunction after IAV infection. <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were infected with 0.04 HAU IAV and lung function was recorded using a Buxco whole-body plethysmography system 7 days after infection for Penh, a measure of calculated airway resistance <bold>(A)</bold>, EF<sub>50</sub>, midbreath expiratory flow <bold>(B)</bold>, and Rpef, the rate of peak expiratory flow <bold>(C)</bold>. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05. **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g006.tif"/>
</fig>
</sec>
<sec id="s3_6">
<title>The Effect of <italic>Par2</italic> Deletion in Either Epithelial or Myeloid Cells on IAV Mortality</title>
<p>A previous study using cultured lung EpCs suggested that PAR2 on lung EpCs contributes to IAV pathology (<xref ref-type="bibr" rid="B23">23</xref>). In addition, other studies implied a major role of PAR2 on myeloid cells for immune response modulation (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Here, we investigated the effect of cell-specific <italic>Par2</italic> deletion in lung EpCs (<italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup>) or myeloid cells (<italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup>) on IAV infection. Body weights were monitored daily after IAV infection and a weight loss &#x2265;25% or actual death were criteria for a mortality event. Body weight curves were constructed showing daily weights of mice remaining who had not met mortality criteria (<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7A, C</bold>
</xref>). <italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup> mice had slightly reduced body weights 7-14dpi compared to controls (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>) but the differences did not reach statistical significance. Moreover, Kaplan-Meier survival analysis showed no significant differences in surviving mice throughout the course of infection for <italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup> mice compared to their controls (<italic>Par2<sup>fl/fl</sup>
</italic>) (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>). <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> mice showed a slightly improved total body weight recovery than control mice (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref>) but again this difference did not reached statistical significance. However, Kaplan-Meier survival curves showed that <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> mice had significantly reduced IAV mortality over the course of the observational period of 14 days when compared to control <italic>Par2<sup>fl/fl</sup>
</italic> mice (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7D</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>PAR2 deficiency on myeloid cells was associated with improved survival after IAV infection. Mice with <italic>Par2</italic> deficiency in lung epithelial cells (<italic>Par2<sup>fl/fl</sup>
</italic>,SPC<sup>Cre+</sup>) or myeloid cells (<italic>Par2<sup>fl/fl</sup>
</italic>,LysM<sup>Cre+</sup>) and their littermates controls (<italic>Par2<sup>fl/fl</sup>)</italic> were infected with 0.04 HAU IAV. Changes in body weights were recorded daily for 14 days after infection <bold>(A, C)</bold>. Overall survival <bold>(B, D)</bold> was observed as well as calculated from body weights for 14 days. A weight loss of &#x2265;25% of the initial body weight was set as compassionate humane endpoint as specified in the animal protocol. Body weights before infection (day 0) were set to 100%. Data (mean &#xb1; SEM) and calculated survival were analyzed by two-way ANOVA <bold>(A, C)</bold> and log-rank test <bold>(B, D)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g007.tif"/>
</fig>
</sec>
<sec id="s3_7">
<title>Myeloid PAR2 Regulates Proinflammatory Response and Neutrophil Accumulation in IAV-Infected Mouse Lungs</title>
<p>Since only <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> mice exhibited a survival benefit after IAV infection compared to <italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup> mice and <italic>Par2<sup>fl/fl</sup>
</italic> mice, we focused the subsequently analysis on <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> mice and compared them to <italic>Par2<sup>fl/fl</sup>
</italic> control mice. BALF of <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> mice and their <italic>Par2<sup>fl/fl</sup>
</italic> controls were analyzed 3dpi and assayed for proinflammatory mediators and immune cell numbers. In line with the improved survival, <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> mice had significantly reduced levels of CXCL1, IL6, and IL12p40 in BALF compared to littermate <italic>Par2<sup>fl/fl</sup>
</italic> controls 3dpi (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8A&#x2013;C</bold>
</xref>). Likewise, decreased total white blood cells and neutrophils numbers were measured in BALF of <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> compared to control <italic>Par2<sup>fl/fl</sup>
</italic> mice 3dpi (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8D, E</bold>
</xref>). There&#xa0;were no significant differences detected in levels of BALF lymphocytes (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8F</bold>
</xref>).</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Myeloid cell <italic>Par2</italic> deficiency results in reduced inflammation in the airspace after IAV infection. <italic>Par2<sup>fl/fl</sup>
</italic>,LysM<sup>Cre+</sup> and their littermate controls <italic>Par2<sup>fl/fl</sup>
</italic> mice were infected with 0.04 HAU IAV and bronchoalveolar lavage fluid (BALF) was analyzed for CXCL1 <bold>(A)</bold>, IL6 <bold>(B)</bold> and IL12p40 <bold>(C)</bold> levels 3 days after infection by ELISA. BALF cellularity was analyzed by automated cell counter for total white blood cell (WBC) <bold>(D)</bold>, neutrophil <bold>(E)</bold> and lymphocyte <bold>(F)</bold> numbers 3 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g008.tif"/>
</fig>
</sec>
<sec id="s3_8">
<title>
<italic>Par2</italic> Deficiency in Myeloid Cells Results in Increased IFN&#x3b2; Expression and Reduced IAV Genome Levels in the Lung</title>
<p>Macrophages are able to restrict/abort IAV replication after infection (<xref ref-type="bibr" rid="B47">47</xref>). However, reduced type-I IFN signaling on macrophages renders the cells more susceptible for productive IAV replication (<xref ref-type="bibr" rid="B47">47</xref>). To analyze the effect of <italic>Par2</italic> deficiency in myeloid cells on lung IFN&#x3b2; expression and overall IAV replication, <italic>Par2<sup>fl/fl</sup>
</italic> and <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup> were infected with IAV and total RNA from lungs isolated 3dpi. Importantly, myeloid cell <italic>Par2</italic> deficient mice had higher IFN&#x3b2; expression in the lung compared to the infected <italic>Par2<sup>fl/fl</sup>
</italic> littermates (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9A</bold>
</xref>). In line with the increased antiviral response in <italic>Par2<sup>fl/fl</sup>
</italic>;LysM<sup>Cre+</sup>, the mice with myeloid <italic>Par2</italic> deficiency had also reduced IAV genome levels in the lung compared to the infected <italic>Par2<sup>fl/f</sup>
</italic> littermates 3dpi (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9B</bold>
</xref>).</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Myeloid <italic>Par2</italic> deficiency was associated with increased IFN&#x3b2; expression but reduced H1N1 IAV virus genomes levels in the IAV infected lung. <italic>Par2<sup>fl/fl</sup>
</italic>,LysM<sup>Cre+</sup> and their littermate controls <italic>Par2<sup>fl/fl</sup>
</italic> mice were infected with 0.04 HAU IAV and IFN&#x3b2; mRNA expression <bold>(A)</bold> and IAV genome levels <bold>(B)</bold> in the lungs were analyzed by RT-PCR 3 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g009.tif"/>
</fig>
</sec>
<sec id="s3_9">
<title>PAR2 Activation Augments Poly I:C Induction of IL6 and IL12p40 Expression in Bone Marrow-Derived Macrophages</title>
<p>BMDM form <italic>Par2<sup>+/+</sup>
</italic> and <italic>Par2<sup>-/-</sup>
</italic> mice were cultured <italic>in vitro</italic> to further evaluate the role of myeloid (macrophage) cell PAR2 in coordinating the inflammatory response to RNA viruses including IAV. The TLR3 agonist poly I:C was used to mimic virus-like stimulation <italic>in vitro</italic>. Poly I:C induced IL6 or IL12p40 expression in both genotypes. However, <italic>Par2<sup>+/+</sup>
</italic> BMDM produced more IL6 and IL12p40 in response to poly I:C when compared to <italic>Par2<sup>-/-</sup>
</italic> BMDM (<xref ref-type="fig" rid="f10">
<bold>Figures&#xa0;10A, B</bold>
</xref>). PAR2 stimulation alone did not significantly increased the IL6 or IL12p40 levels over the baseline. Importantly, <italic>Par2<sup>+/+</sup>
</italic> BMDM costimulated with PAR2 AP and poly I:C express significantly higher levels of IL6 or IL12p40 compared to poly I:C alone. As expected, the PAR2 AP did not elicit an increased response in <italic>Par2</italic>
<sup>-/-</sup> BMDM treated with poly I:C (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>).</p>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>PAR2 activation of macrophages increases IL6 and IL12p40 expression during TLR3 stimulation. Bone-marrow derived macrophages were stimulated with poly I:C (5&#xb5;g/mL) and/or PAR2 agonist (AP, 200&#xb5;M) under serum-free conditions. IL6 <bold>(A)</bold> and IL12p40 <bold>(B)</bold> levels were measured in the culture media 24 hrs after stimulation by ELISAs. Data (mean &#xb1; SEM) was analyzed by 2-Way ANOVA. *P &lt; 0.05, <italic># vs</italic>. unstimulated control within the same genotype, <sup>$</sup>P &lt; 0.05 <italic>vs</italic>. poly I:C alone within the same genotype.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g010.tif"/>
</fig>
</sec>
<sec id="s3_10">
<title>PAR2 Inhibition Results in Decreased Cytokine Production in the MouseLung After IAV Infection</title>
<p>To evaluate the potential of intranasal PAR2 antagonist treatment to reduce pathologic inflammation in the lung after IAV infection, WT mice were treated with an inhibitory PAR2 antibody (SAM11) or control IgG<sub>2a</sub> prior and during infection with IAV. BALF of mice treated with SAM11 or IgG<sub>2a</sub> control was collected at 3dpi and assayed for proinflammatory mediators and cellular infiltrate. SAM11 treatment resulted in significantly reduced levels of CXCL1, IL-6, and IL-12p40 in BALF compared control IgG<sub>2a</sub>-treated mice 3dpi (<xref ref-type="fig" rid="f11">
<bold>Figures&#xa0;11A&#x2013;C</bold>
</xref>). In line with this, SAM11-treated mice had decreased total white blood cells in BALF compared to IgG<sub>2a</sub>-treated controls (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11D</bold>
</xref>). While SAM11 treatment did not change the expression of IFN&#x3b2; it resulted in reduced overall IAV genome levels in the lung compared to IgG<sub>2a</sub> treated mice 3dpi (<xref ref-type="fig" rid="f11">
<bold>Figures&#xa0;11E, F</bold>
</xref>).</p>
<fig id="f11" position="float">
<label>Figure&#xa0;11</label>
<caption>
<p>PAR2 inhibition prior to infection resulted in reduced inflammation in the lung after IAV infection. WT mice were treated intranasally with anti-mouse PAR2 antibody (SAM11) prior to infection with 0.04 HAU IAV and then daily for 3 days (see <italic>Methods</italic> for additional information). Bronchoalveolar lavage fluid (BALF) was collected at day 3 post IAV infection and analyzed for CXCL1 <bold>(A)</bold>, IL6 <bold>(B)</bold> and IL12p40 <bold>(C)</bold> levels by ELISA. White blood cells (WBC) numbers <bold>(D)</bold> were analyzed by automated cell counter. Lung IFN&#x3b2; mRNA expression <bold>(E)</bold> and IAV genome levels <bold>(F)</bold> were analyzed by RT-PCR 3 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g011.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we showed that PAR2 contributes to IAV infection-induced mortality in mice. In addition, we found that PAR2 contributes to increased cytokine expression and immune cell infiltration into the air space (BALF) leading to more pronounced global lung dysfunction in mice after IAV infection. Using mice with cell-specific deletion of <italic>Par2</italic>, we observed that myeloid-expressed PAR2, but not lung EpC PAR2 contributed to IAV pathology. Importantly, prophylactic PAR2 inhibition using an anti-mouse PAR2 antibody reduced IAV progression in mice.</p>
<p>Based on our studies of PARs in ssRNA virus infections, as well by others, we proposed a model in which PAR2 enhances TLR3-NF&#x3ba;B inflammation but reduces TLR3-type-I IFN responses. In contrast, PAR1 reduces TLR3-NF&#x3ba;B inflammation but enhances TLR3-IFN&#x3b2; responses (<xref ref-type="fig" rid="f12">
<bold>Figure&#xa0;12</bold>
</xref>) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B48">48</xref>). In line with this proposed receptor interaction, we have recently shown that the absence of PAR1 leads to increased proinflammatory CXCL1 expression and increased BALF neutrophil numbers which were associated with higher mortality compared to WT mice (<xref ref-type="bibr" rid="B26">26</xref>).</p>
<fig id="f12" position="float">
<label>Figure&#xa0;12</label>
<caption>
<p>Proposed model how PAR2 and PAR1 modulates TLR3 responses during influenza A virus infection. <bold>(A)</bold> PAR2 enhances and PAR1 dampens TLR3-NF&#x3ba;B-dependent expression of inflammatory markers in the bronchoalveolar lavage fluid after influenza A virus (IAV) infection. <bold>(B)</bold> With regard to the anti-viral TLR3-IFN&#x3b2; response, PAR2 dampens and PAR1 enhances IFN&#x3b2; expression in the lung after IAV infection. See main text for additional information. CXCL1, C-X-C Motif Chemokine Ligand 1; IFN&#x3b2;, interferon-beta; IL6, interleukin 6; PAR, protease activated receptor; TLR3, toll-like receptor 3. Figure created on <uri xlink:href="https://biorender.com">Biorender.com</uri>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-791017-g012.tif"/>
</fig>
<p>There are conflicting data about the role of PAR2 in IAV infection in mice and cells <italic>in vitro</italic>. Our data presented here are consistent with the observation by Vogel&#x2019;s group that <italic>Par2</italic> deficiency was associated with improved survival after IAV infection (<xref ref-type="bibr" rid="B23">23</xref>). Importantly, we used a different line of <italic>Par2</italic>-deficient mice (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B49">49</xref>) compared with Nhu et&#xa0;al. (<xref ref-type="bibr" rid="B23">23</xref>) but made similar observations after IAV infection supporting a role of PAR2 in IAV pathology. In contrast to our and Vogel&#x2019;s findings, Riteau&#x2019;s group showed that <italic>Par2<sup>-/-</sup>
</italic> mice exhibited increased mortality after IAV infection with either 30 plaque-forming units (pfu) or 60 pfu (<xref ref-type="bibr" rid="B50">50</xref>). Interestingly, using this dose the authors did not induce any body weight changes or death in WT mice (<xref ref-type="bibr" rid="B50">50</xref>). Moreover, studies using the specific PAR2 AP (SLIGRL-NH<sub>2</sub>) suggested that PAR2 activation mediates a protective mechanism in IAV infection in mice and in <italic>in vitro</italic> cell culture system (<xref ref-type="bibr" rid="B50">50</xref>&#x2013;<xref ref-type="bibr" rid="B55">55</xref>). However, SLIGRL-NH<sub>2</sub> has been reported to inhibit IAV infection in mice and <italic>in vitro</italic> independently of PAR2 (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B55">55</xref>).</p>
<p>In general, IAV infection-mediated pathology is caused by a lack of adequate innate antiviral immune responses causing virus induced injury which can be exacerbated by an excessive proinflammatory response (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Importantly, the overreacting host&#x2019;s immune response appears to contribute to the morbidity and mortality after IAV infection (<xref ref-type="bibr" rid="B41">41</xref>). For instance, TLR3-deficient mice exhibited improved survival associated with reduced lung inflammation while having an increased virus load after IAV infection compared to WT mice (<xref ref-type="bibr" rid="B56">56</xref>). Nhu et&#xa0;al. showed that PAR2 activation increased NF&#x3ba;B responses but reduced type-I IFN responses during TLR3 stimulation of lung EpCs (<xref ref-type="bibr" rid="B23">23</xref>). By extrapolation of their <italic>in vitro</italic> observations, the authors suggested that PAR2 activation on lung EpCs would contribute to IAV pathology <italic>in vivo</italic> (<xref ref-type="bibr" rid="B23">23</xref>). We did not observe a lung EpC PAR2-dependent mortality phenotype in our IAV infection model. However, body weight recovery seemed different between <italic>Par2<sup>fl/fl</sup>
</italic> and <italic>Par2<sup>fl/fl</sup>
</italic>;SPC<sup>Cre+</sup> mice suggesting a protective role for EpC PAR2 in maintaining barrier function (<xref ref-type="bibr" rid="B57">57</xref>). The mouse-adapted PR8 IAV strain is highly pathogenic and might overwhelm any PAR2-dependent effects in EpCs <italic>in vivo</italic>. However, we found that myeloid PAR2 expressing cells increased NF&#x3ba;B-associated lung inflammation in PR8 IAV infected mice. Moreover, we found that PAR2 expression further reduced IFN&#x3b2; expression in the lung 3dpi. Using BMDM, we confirmed that PAR2 expression and activation increased the release of the two NF&#x3ba;B-dependent cytokines IL6 and IL12p40 during TLR3 stimulation <italic>in vitro</italic>. Moreover, neutrophils can play a protective as well as detrimental role in IAV infection, and PAR2 stimulation can increase neutrophil activity (<xref ref-type="bibr" rid="B53">53</xref>). While neutrophil depletion led to increased IAV infection, an overactivation and increased neutrophil recruitment to the lung after IAV infection was shown to be associated with increased IAV-induced pathology and death (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B58">58</xref>). Although neutrophils are of myeloid lineage and targets of LysM<sup>Cre</sup>-activity (<xref ref-type="bibr" rid="B30">30</xref>), we did not specifically address whether PAR2 on neutrophils plays a role on IAV progression in this study.</p>
<p>Together with past studies using other viruses, including IAV and Coxsackievirus B3, or sterile virus-like stimulation with poly I:C, this study indicates that PAR2 expression and activation contributes to viral infection-associated pathology by enhancing proinflammatory TLR3-NF&#x3ba;B responses and reducing antiviral TLR3-IFN&#x3b2; responses as first suggested first by Nhu et&#xa0;al. (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B59">59</xref>&#x2013;<xref ref-type="bibr" rid="B61">61</xref>). How does PAR2 mediate its effect on TLR3 signaling? As previous demonstrated by Vogel&#x2019;s group (<xref ref-type="bibr" rid="B62">62</xref>), we showed that PAR2 can be immunoprecipitated with TLR4 and TLR3 (<xref ref-type="bibr" rid="B43">43</xref>). It is not clear if the physical interaction alone can explain the observed phenotype. While PAR2 has no immediate effect on IFN&#x3b2; signaling (within the first 15 min) (<xref ref-type="bibr" rid="B23">23</xref>)  but it reduces IFN&#x3b2; signaling at later stages (past 180 min) (<xref ref-type="bibr" rid="B61">61</xref>). Whether PAR2 activation directly dampens IFN&#x3b2;-dependent STAT1 activation, increases STAT1 dephosphorylation or reduces interferon-&#x3b1;/&#x3b2; receptor surface expression is unclear. Of note, PAR2-dependent reduction of the TLR3-IFN&#x3b2; pathway activation was linked to PAR2-dependent activity of the tyrosine phosphatase SH2 domain-containing protein tyrosine phosphatase-2 (SHP-2, protein tyrosine phosphatases [PTP] 11) (<xref ref-type="bibr" rid="B61">61</xref>). In line with our findings, SHP-2 activity was shown to be important for efficient NF&#x3ba;B activation (<xref ref-type="bibr" rid="B63">63</xref>). Moreover, <italic>in vivo</italic> PAR2 AP stimulation of murine urinary bladders increased the expression of the dual specificity phosphatase 1 (DUSP1, mitogen-activated protein kinase [MAPK] phosphatase 1) (<xref ref-type="bibr" rid="B64">64</xref>) which is known to inactivate the MAPKs JNK and p38. Interestingly, DUSP1 expression/activity reduces TLR3-mediated IFN&#x3b2; expression in macrophages by reducing JNK-dependent IFN&#x3b2; gene transcription and reducing p38-dependent IFN&#x3b2; mRNA stability (<xref ref-type="bibr" rid="B65">65</xref>).</p>
<p>PAR2 can be activated by a variety of proteases including trypsin, tryptase, neutrophil elastase, different membrane-bound proteases, the tissue factor (TF)/FVIIa complex, or FXa alone. We&#xa0;showed that IAV infection increases lung EpC TF expression which leads to IAV-associated local activation of coagulation (<xref ref-type="bibr" rid="B27">27</xref>). This suggests that the TF/FVIIa complex is formed and FXa is generated locally during IAV infection in the lung which could in turn lead to PAR2 activation. Immune cell expressed proteases are also present in the lung during IAV infection and pulmonary expressed membrane-bound proteases including transmembrane protease serine type 2 (TMPRSS2), matriptase or human airway trypsin-like protease are known to activate PAR2 (<xref ref-type="bibr" rid="B66">66</xref>&#x2013;<xref ref-type="bibr" rid="B68">68</xref>). Interestingly, TMPRSS2 deficiency was shown to reduce inflammatory responses to intranasal poly I:C (<xref ref-type="bibr" rid="B69">69</xref>). In an IAV-induced myocarditis model, local trypsin expression was associated with increased cardiac pathology (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>). However, the authors did not link the increased trypsin expression to increased PAR2 signaling. Importantly, PAR2-activating proteases are involved in the proteolytic activation of IAV (<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B73">73</xref>). In line with this, serine protease inhibitors, including aprotinin (<xref ref-type="bibr" rid="B74">74</xref>) and camostat mesylate (<xref ref-type="bibr" rid="B75">75</xref>), were shown to directly reduce IAV infectivity and might also reduce protease-dependent PAR2 activation during IAV infection.</p>
<p>Antiviral treatments for influenza virus infections are limited (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). We show that PAR2 inhibition prior to infection not only reduced IAV virus genome levels in the lung 3dpi but also reduced cytokine/chemokine and cellular inflammation in the BALF compared to control IgG treated mice. In support to our findings, PAR2 inhibition reduced immune cell infiltration into the lung/airspace of respiratory syncytial virus infected mice (<xref ref-type="bibr" rid="B78">78</xref>). These findings suggest that PAR2 might be a therapeutic target in reducing respiratory viral infection, including pandemic coronavirus infections (<xref ref-type="bibr" rid="B79">79</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>).</p>
<p>In conclusion, we linked myeloid cell PAR2 to the IAV pathology in mice. PAR2 not only reduces antiviral type-I IFN responses but also enhances NF&#x3ba;B-dependent inflammation in the lung of IAV infected mice resulting in increased BALF cellularity, which was associated with increased lung EpC injury, overall more pronounced global lung dysfunction and higher mortality. Moreover, we show that PAR2-directed therapeutics have the potential not only to enhance antiviral immune responses to IAV but also to reduce host-driven pathologic lung inflammation.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the corresponding author, without undue reservation.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics Statement</title>
<p>The animal study was reviewed, approved and performed in accordance with the guidelines of the animal care and use committee of the University of North Carolina at Chapel Hill and complies with National Institutes of Health guidelines.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author Contributions</title>
<p>RG, VB, SDM, LT, CS, KT, MDB, and DM conducted experiments. SAM performed the blinded histological evaluation of the lung sections and provided additional data interpretation. RG, NM, and SA interpreted the data and wrote the manuscript. MB and EC provided essential materials and edited the manuscript. NM and SA provided funding. SA&#xa0;designed and overviewed the study. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The presented study was supported by grants from the NHLBI to NM (1R35HL155657) and SA (1R01HL142799).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We want to thank Ying Zhang for excellent technical assistance.</p>
</ack>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2021.791017/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2021.791017/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.tif" id="SF1" mimetype="image/tiff">
<label>Supplement Figure 1</label>
<caption>
<p>PAR2 deficiency was associated with reduced eosinophil numbers in the airspace 3 days after IAV infection. <italic>Par2</italic>
<sup>+/+</sup> and <italic>Par2</italic>
<sup>-/-</sup> mice were infected with 0.04 HAU IAV and eosinophil numbers in bronchoalveolar lavage fluid (BALF) was analyzed by automated cell counter 3 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_2.tif" id="SF2" mimetype="image/tiff">
<label>Supplement Figure 2</label>
<caption>
<p>Cytokine levels in airspace of <italic>Par2</italic>
<sup>+/+</sup> and <italic>Par2</italic>
<sup>-/-</sup> mice 7 days after influenza A virus infection. <italic>Par2</italic>
<sup>+/+</sup> and <italic>Par2</italic>
<sup>-/-</sup> mice were infected with 0.04 HAU IAV and bronchoalveolar lavage fluid (BALF) was analyzed for TNF&#x3b1; <bold>(A)</bold>, MCP-1 <bold>(B)</bold>, CXCL1 <bold>(C)</bold>, IL6 <bold>(D)</bold> and IL12p40 <bold>(E)</bold> protein levels 7 days after infection by ELISA. Data (mean &#xb1; SEM) was analyzed by Student t test. ***P &lt; 0.005.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_3.tif" id="SF3" mimetype="image/tiff">
<label>Supplement Figure 3</label>
<caption>
<p>PAR2 deficiency was associated with reduced immune cell numbers in the airspace 7 days after influenza A virus infection. <italic>Par2</italic>
<sup>+/+</sup> and <italic>Par2</italic>
<sup>-/-</sup> mice were infected with 0.04 HAU IAV and bronchoalveolar lavage fluid (BALF) cellularity was analyzed by automated cell counter for total white blood cell (WBC) <bold>(A)</bold>, neutrophil <bold>(B)</bold>, monocyte <bold>(C)</bold>, lymphocyte <bold>(D)</bold> and eosinophil <bold>(E)</bold> numbers 7 days after infection. Data (mean &#xb1; SEM) was analyzed by Student t test. *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lafond</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Porter</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Whaley</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Suizan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ran</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Aleem</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Global Burden of Influenza-Associated Lower Respiratory Tract Infections and Hospitalizations Among Adults: A Systematic Review and Meta-Analysis</article-title>. <source>PloS Med</source> (<year>2021</year>) <volume>18</volume>(<issue>3</issue>):<fpage>e1003550</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.1003550</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adlhoch</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gomes Dias</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bonmarin</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hubert</surname> <given-names>B</given-names>
</name>
<name>
<surname>Larrauri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oliva Dominguez</surname> <given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union 2009-2017</article-title>. <source>Open Forum Infect Dis</source> (<year>2019</year>) <volume>6</volume>(<issue>11</issue>):<fpage>ofz462</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ofid/ofz462</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalil</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>PG</given-names>
</name>
</person-group>. <article-title>Influenza Virus-Related Critical Illness: Pathophysiology and Epidemiology</article-title>. <source>Crit Care</source> (<year>2019</year>) <volume>23</volume>(<issue>1</issue>):<fpage>258</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13054-019-2539-x</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kaisho</surname> <given-names>T</given-names>
</name>
<name>
<surname>Akira</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Toll-Like Receptors</article-title>. <source>Annu Rev Immunol</source> (<year>2003</year>) <volume>21</volume>(<issue>1</issue>):<page-range>335&#x2013;76</page-range>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141126</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mateer</surname> <given-names>E</given-names>
</name>
<name>
<surname>Paessler</surname> <given-names>S</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection</article-title>. <source>J&#xa0;Vis Exp</source> (<year>2019</year>) (<volume>143</volume>):<fpage>e59095</fpage>. doi: <pub-id pub-id-type="doi">10.3791/59095</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname> <given-names>KN</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lipton</surname> <given-names>HL</given-names>
</name>
</person-group>. <article-title>Double-Stranded RNA Is Detected by Immunofluorescence Analysis in RNA and DNA Virus Infections, Including Those by Negative-Stranded RNA Viruses</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>89</volume>(<issue>18</issue>):<page-range>9383&#x2013;92</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01299-15</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwasaki</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pillai</surname> <given-names>PS</given-names>
</name>
</person-group>. <article-title>Innate Immunity to Influenza Virus Infection</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>(<issue>5</issue>):<page-range>315&#x2013;28</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3665</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mackman</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Multiple Roles of the Coagulation Protease Cascade During Virus Infection</article-title>. <source>Blood</source> (<year>2014</year>) <volume>123</volume>(<issue>17</issue>):<page-range>2605&#x2013;13</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2013-09-526277</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goffic</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Balloy</surname> <given-names>V</given-names>
</name>
<name>
<surname>Lagranderie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Alexopoulou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Escriou</surname> <given-names>N</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Detrimental Contribution of the Toll-Like Receptor (TLR)3 to Influenza A Virus&#x2013;Induced Acute Pneumonia</article-title>. <source>PloS Pathog</source> (<year>2006</year>) <volume>2</volume>(<issue>6</issue>):<fpage>e53</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.0020053</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manicassamy</surname> <given-names>B</given-names>
</name>
<name>
<surname>Manicassamy</surname> <given-names>S</given-names>
</name>
<name>
<surname>Belicha-Villanueva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pisanelli</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pulendran</surname> <given-names>B</given-names>
</name>
<name>
<surname>Garc&#xed;a-Sastre</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Analysis of <italic>In Vivo</italic> Dynamics of Influenza Virus Infection in Mice Using a GFP Reporter Virus</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2010</year>) <volume>107</volume>(<issue>25</issue>):<page-range>11531&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0914994107</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steuerman</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cohen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Peshes-Yaloz</surname> <given-names>N</given-names>
</name>
<name>
<surname>Valadarsky</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cohn</surname> <given-names>O</given-names>
</name>
<name>
<surname>David</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Dissection of Influenza Infection <italic>In Vivo</italic> by Single-Cell RNA Sequencing</article-title>. <source>Cell Syst</source> (<year>2018</year>) <volume>6</volume>(<issue>6</issue>):<fpage>679</fpage>&#x2013;<lpage>91.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cels.2018.05.008</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cline</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Beck</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bianchini</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Influenza Virus Replication in Macrophages: Balancing Protection and Pathogenesis</article-title>. <source>J Gen Virol</source> (<year>2017</year>) <volume>98</volume>(<issue>10</issue>):<page-range>2401&#x2013;12</page-range>. doi: <pub-id pub-id-type="doi">10.1099/jgv.0.000922</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumagai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Takeuchi</surname> <given-names>O</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>H</given-names>
</name>
<name>
<surname>Matsui</surname> <given-names>K</given-names>
</name>
<name>
<surname>Morii</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Alveolar Macrophages Are the Primary Interferon-Alpha Producer in Pulmonary Infection With RNA Viruses</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>27</volume>(<issue>2</issue>):<page-range>240&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2007.07.013</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hogner</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wolff</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pleschka</surname> <given-names>S</given-names>
</name>
<name>
<surname>Plog</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gruber</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Kalinke</surname> <given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage-Expressed IFN-Beta Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia</article-title>. <source>PloS Pathog</source> (<year>2013</year>) <volume>9</volume>(<issue>2</issue>):<fpage>e1003188</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1003188</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname> <given-names>C</given-names>
</name>
<name>
<surname>Nobs</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Heer</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Kurrer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Klinke</surname> <given-names>G</given-names>
</name>
<name>
<surname>van Rooijen</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Alveolar Macrophages Are Essential for Protection From Respiratory Failure and Associated Morbidity Following Influenza Virus Infection</article-title>. <source>PloS Pathog</source> (<year>2014</year>) <volume>10</volume>(<issue>4</issue>):<fpage>e1004053</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1004053</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YW</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>SW</given-names>
</name>
<name>
<surname>van Rooijen</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Alveolar Macrophages Are Indispensable for Controlling Influenza Viruses in Lungs of Pigs</article-title>. <source>J Virol</source> (<year>2008</year>) <volume>82</volume>(<issue>9</issue>):<page-range>4265&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02602-07</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cole</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Ho</surname> <given-names>LP</given-names>
</name>
</person-group>. <article-title>Contribution of Innate Immune Cells to Pathogenesis of Severe Influenza Virus Infection</article-title>. <source>Clin Sci (Lond)</source> (<year>2017</year>) <volume>131</volume>(<issue>4</issue>):<page-range>269&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.1042/CS20160484</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagan</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Torres-Castillo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Doerschuk</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>Myeloid TBK1 Signaling Contributes to the Immune Response to Influenza</article-title>. <source>Am J Respir Cell Mol Biol</source> (<year>2019</year>) <volume>60</volume>(<issue>3</issue>):<page-range>335&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1165/rcmb.2018-0122OC</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herold</surname> <given-names>S</given-names>
</name>
<name>
<surname>Steinmueller</surname> <given-names>M</given-names>
</name>
<name>
<surname>von Wulffen</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cakarova</surname> <given-names>L</given-names>
</name>
<name>
<surname>Pinto</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pleschka</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Lung Epithelial Apoptosis in Influenza Virus Pneumonia: The Role of Macrophage-Expressed TNF-Related Apoptosis-Inducing Ligand</article-title>. <source>J Exp Med</source> (<year>2008</year>) <volume>205</volume>(<issue>13</issue>):<page-range>3065&#x2013;77</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20080201</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>X</given-names>
</name>
<name>
<surname>Nieman</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Kerlin</surname> <given-names>BA</given-names>
</name>
</person-group>. <article-title>Protease-Activated Receptors: An Illustrated Review</article-title>. <source>Res Pract Thromb Haemost</source> (<year>2021</year>) <volume>5</volume>(<issue>1</issue>):<fpage>17</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1002/rth2.12454</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Stewart</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Goldie</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Henry</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Altered Expression and <italic>In Vivo</italic> Lung Function of Protease-Activated Receptors During Influenza A Virus Infection in Mice</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2004</year>) <volume>286</volume>(<issue>2</issue>):<page-range>L388&#x2013;98</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajplung.00286.2003</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bellocchio</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bonifazi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bozza</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zelante</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bistoni</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>The Contribution of PARs to Inflammation and Immunity to Fungi</article-title>. <source>Mucosal Immunol</source> (<year>2008</year>) <volume>1</volume>(<issue>2</issue>):<page-range>156&#x2013;68</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mi.2007.13</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nhu</surname> <given-names>QM</given-names>
</name>
<name>
<surname>Shirey</surname> <given-names>K</given-names>
</name>
<name>
<surname>Teijaro</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Farber</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Netzel-Arnett</surname> <given-names>S</given-names>
</name>
<name>
<surname>Antalis</surname> <given-names>TM</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel Signaling Interactions Between Proteinase-Activated Receptor 2 and Toll-Like Receptors <italic>In Vitro</italic> and <italic>In Vivo</italic>
</article-title>. <source>Mucosal Immunol</source> (<year>2010</year>) <volume>3</volume>(<issue>1</issue>):<fpage>29</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mi.2009.120</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damiano</surname> <given-names>BP</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Santulli</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Fung-Leung</surname> <given-names>WP</given-names>
</name>
<name>
<surname>Ngo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiovascular Responses Mediated by Protease-Activated Receptor-2 (PAR-2) and Thrombin Receptor (PAR-1) Are Distinguished in Mice Deficient in PAR-2 or PAR-1</article-title>. <source>J Pharmacol Exp Ther</source> (<year>1999</year>) <volume>288</volume>(<issue>2</issue>):<page-range>671&#x2013;8</page-range>.</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skarnes</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Rosen</surname> <given-names>B</given-names>
</name>
<name>
<surname>West</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Koutsourakis</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bushell</surname> <given-names>W</given-names>
</name>
<name>
<surname>Iyer</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>A Conditional Knockout Resource for the Genome-Wide Study of Mouse Gene Function</article-title>. <source>Nature</source> (<year>2011</year>) <volume>474</volume>(<issue>7351</issue>):<page-range>337&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature10163</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tatsumi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Schmedes</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Egnatz</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Auriemma</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Bharathi</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>PAR1 Regulation of CXCL1 Expression and Neutrophil Recruitment to the Lung in Mice Infected With Influenza A Virus</article-title>. <source>J Thromb haemostasis JTH</source> (<year>2021</year>) <volume>19</volume>(<issue>4</issue>):<page-range>1103&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jth.15221</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tatsumi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hisada</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Milner</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Neidich</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Shaver</surname> <given-names>CM</given-names>
</name>
<etal/>
</person-group>. <article-title>Tissue Factor Deficiency Increases Alveolar Hemorrhage and Death in Influenza A Virus-Infected Mice</article-title>. <source>J Thromb Haemostasis JTH</source> (<year>2016</year>) <volume>14</volume>(<issue>6</issue>):<page-range>1238&#x2013;48</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jth.13307</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graf</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wilgenbus</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pagel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pott</surname> <given-names>J</given-names>
</name>
<name>
<surname>Marini</surname> <given-names>F</given-names>
</name>
<name>
<surname>Reyda</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Myeloid Cell&#x2013;Synthesized Coagulation Factor X Dampens Antitumor Immunity</article-title>. <source>Sci Immunol</source> (<year>2019</year>) <volume>4</volume>(<issue>39</issue>):<fpage>eaaw8405</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.aaw8405</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saffarzadeh</surname> <given-names>M</given-names>
</name>
<name>
<surname>Grunz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YK</given-names>
</name>
<name>
<surname>Kitano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Danckwardt</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage Protease-Activated Receptor 2 Regulates Fetal Liver Erythropoiesis in Mice</article-title>. <source>Blood Adv</source> (<year>2020</year>) <volume>4</volume>(<issue>22</issue>):<page-range>5810&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1182/bloodadvances.2020003299</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abram</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Roberge</surname> <given-names>GL</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lowell</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>Comparative Analysis of the Efficiency and Specificity of Myeloid-Cre Deleting Strains Using ROSA-EYFP Reporter Mice</article-title>. <source>J Immunol Methods</source> (<year>2014</year>) <volume>408</volume>:<fpage>89</fpage>&#x2013;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2014.05.009</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schweickert</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>White</surname> <given-names>EE</given-names>
</name>
<name>
<surname>Cresswell</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Elzey</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Ratliff</surname> <given-names>TL</given-names>
</name>
<etal/>
</person-group>. <article-title>Thrombin-PAR1 Signaling in Pancreatic Cancer Promotes an Immunosuppressive Microenvironment</article-title>. <source>J Thromb haemostasis JTH</source> (<year>2021</year>) <volume>19</volume>(<issue>1</issue>):<page-range>161&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jth.15115</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatsumi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Subramaniam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gondouin</surname> <given-names>B</given-names>
</name>
<name>
<surname>Neidich</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Beck</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Anticoagulation Increases Alveolar Hemorrhage in Mice Infected With Influenza a</article-title>. <source>Physiol Rep</source> (<year>2016</year>) <volume>4</volume>(<issue>24</issue>):<fpage>e13071</fpage>. doi: <pub-id pub-id-type="doi">10.14814/phy2.13071</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatsumi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Schmedes</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Houston</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Butler</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mackman</surname> <given-names>N</given-names>
</name>
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Protease-Activated Receptor 4 Protects Mice From Coxsackievirus B3 and H1N1 Influenza A Virus Infection</article-title>. <source>Cell Immunol</source> (<year>2019</year>) <volume>344</volume>:<fpage>103949</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cellimm.2019.103949</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asaduzzaman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nadeem</surname> <given-names>A</given-names>
</name>
<name>
<surname>Arizmendi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Davidson</surname> <given-names>C</given-names>
</name>
<name>
<surname>Nichols</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Abel</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional Inhibition of PAR2 Alleviates Allergen-Induced Airway Hyperresponsiveness and Inflammation</article-title>. <source>Clin Exp Allergy J Br Soc Allergy Clin Immunol</source> (<year>2015</year>) <volume>45</volume>(<issue>12</issue>):<page-range>1844&#x2013;55</page-range>. doi: <pub-id pub-id-type="doi">10.1111/cea.12628</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natiello</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kelly</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lamca</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zelmnovic</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chapman</surname> <given-names>R</given-names>
</name>
<name>
<surname>Phillips</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Manual and Automated Leukocyte Differentiation in Bronchoalveolar Lavage Fluids From Rodent Models of Pulmonary Inflammation</article-title>. <source>Comp Clin Pathol</source> (<year>2009</year>) <volume>18</volume>(<issue>2</issue>):<page-range>101&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00580-008-0772-9</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Owens AP</surname> <given-names>III</given-names>
</name>
<name>
<surname>Baunacke</surname> <given-names>M</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Weith&#xe4;user</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>PAR-1 Contributes to the Innate Immune Response During Viral Infection</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>(<issue>3</issue>):<page-range>1310&#x2013;22</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI66125</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davenport</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Sherrill</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Blackwell</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Edmonds</surname> <given-names>MD</given-names>
</name>
</person-group>. <article-title>Perfusion and Inflation of the Mouse Lung for Tumor Histology</article-title>. <source>J Vis Exp</source> (<year>2020</year>) <volume>(162)</volume>:<fpage>10.3791/60605</fpage>. doi: <pub-id pub-id-type="doi">10.3791/60605</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinnon</surname> <given-names>KH</given-names> <suffix>3rd</suffix>
</name>
<name>
<surname>Leist</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Schafer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Montgomery</surname> <given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>A Mouse-Adapted Model of SARS-CoV-2 to Test COVID-19 Countermeasures</article-title>. <source>Nature</source> (<year>2020</year>) <volume>586</volume>(<issue>7830</issue>):<page-range>560&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2708-8</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menachery</surname> <given-names>VD</given-names>
</name>
<name>
<surname>Gralinski</surname> <given-names>LE</given-names>
</name>
<name>
<surname>Baric</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Ferris</surname> <given-names>MT</given-names>
</name>
</person-group>. <article-title>New Metrics for Evaluating Viral Respiratory Pathogenesis</article-title>. <source>PloS One</source> (<year>2015</year>) <volume>10</volume>(<issue>6</issue>):<fpage>e0131451</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0131451</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tatsumi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Bode</surname> <given-names>M</given-names>
</name>
<name>
<surname>Vanja</surname> <given-names>S</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Mackman</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Protease-Activated Receptor 1 Enhances Poly I:C Induction of the Antiviral Response in Macrophages and Mice</article-title>. <source>J Innate Immun</source> (<year>2017</year>) <volume>9</volume>(<issue>2</issue>):<page-range>181&#x2013;92</page-range>. doi: <pub-id pub-id-type="doi">10.1159/000450853</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balachandran</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rall</surname> <given-names>GF</given-names>
</name>
</person-group>. <article-title>Benefits and Perils of Necroptosis in Influenza Virus Infection</article-title>. <source>J Virol</source> (<year>2020</year>) <volume>94</volume>(<issue>9</issue>):<page-range>e01101&#x2013;19</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01101-19</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seo</surname> <given-names>SU</given-names>
</name>
<name>
<surname>Kwon</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Ko</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Byun</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Seong</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Uematsu</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Type I Interferon Signaling Regulates Ly6C(hi) Monocytes and Neutrophils During Acute Viral Pneumonia in Mice</article-title>. <source>PloS Pathog</source> (<year>2011</year>) <volume>7</volume>(<issue>2</issue>):<fpage>e1001304</fpage>.  doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1001304</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weithauser</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bobbert</surname> <given-names>P</given-names>
</name>
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bohm</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rauch</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Klingel</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Protease-Activated Receptor-2 Regulates the Innate Immune Response to Viral Infection in a Coxsackievirus B3-Induced Myocarditis</article-title>. <source>J Am Coll Cardiol</source> (<year>2013</year>) <volume>62</volume>(<issue>19</issue>):<page-range>1737&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2013.05.076</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Major</surname> <given-names>J</given-names>
</name>
<name>
<surname>Crotta</surname> <given-names>S</given-names>
</name>
<name>
<surname>Llorian</surname> <given-names>M</given-names>
</name>
<name>
<surname>McCabe</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Gad</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Priestnall</surname> <given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Type I and III Interferons Disrupt Lung Epithelial Repair During Recovery From Viral Infection</article-title>. <source>Science</source> (<year>2020</year>) <volume>369</volume>(<issue>6504</issue>):<page-range>712&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.abc2061</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Vogel</surname> <given-names>P</given-names>
</name>
<name>
<surname>McClaren</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Bajracharya</surname> <given-names>R</given-names>
</name>
<name>
<surname>Doherty</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>PG</given-names>
</name>
</person-group>. <article-title>Compromised Respiratory Function in Lethal Influenza Infection Is Characterized by the Depletion of Type I Alveolar Epithelial Cells Beyond Threshold Levels</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2013</year>) <volume>304</volume>(<issue>7</issue>):<page-range>L481&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajplung.00343.2012</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruf</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Roles of Factor Xa Beyond Coagulation</article-title>. <source>J Thromb Thrombolysis</source> (<year>2021</year>) <volume>52</volume>(<issue>2</issue>):<page-range>391&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11239-021-02458-8</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Londrigan</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Wakim</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>J</given-names>
</name>
<name>
<surname>Haverkate</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Brooks</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Reading</surname> <given-names>PC</given-names>
</name>
</person-group>. <article-title>IFITM3 and Type I Interferons are Important for the Control of Influenza A Virus Replication in Murine Macrophages</article-title>. <source>Virology</source> (<year>2020</year>) <volume>540</volume>:<fpage>17</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virol.2019.11.003</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mackman</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Coagulation, Protease-Activated Receptors, and Viral Myocarditis</article-title>. <source>J Cardiovasc Transl Res</source> (<year>2014</year>) <volume>7</volume>(<issue>2</issue>):<page-range>203&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s12265-013-9515-7</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidlin</surname> <given-names>F</given-names>
</name>
<name>
<surname>Amadesi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dabbagh</surname> <given-names>K</given-names>
</name>
<name>
<surname>Lewis</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Knott</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bunnett</surname> <given-names>NW</given-names>
</name>
<etal/>
</person-group>. <article-title>Protease-Activated Receptor 2 Mediates Eosinophil Infiltration and Hyperreactivity in Allergic Inflammation of the Airway</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>169</volume>(<issue>9</issue>):<page-range>5315&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.169.9.5315</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoufache</surname> <given-names>K</given-names>
</name>
<name>
<surname>LeBouder</surname> <given-names>F</given-names>
</name>
<name>
<surname>Morello</surname> <given-names>E</given-names>
</name>
<name>
<surname>Laurent</surname> <given-names>F</given-names>
</name>
<name>
<surname>Riffault</surname> <given-names>S</given-names>
</name>
<name>
<surname>Andrade-Gordon</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Protective Role for Protease-Activated Receptor-2 Against Influenza Virus Pathogenesis <italic>via</italic> an IFN-Gamma-Dependent Pathway</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>(<issue>12</issue>):<page-range>7795&#x2013;802</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0803743</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>G</given-names>
</name>
<name>
<surname>Hollenberg</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Vliagoftis</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kane</surname> <given-names>KP</given-names>
</name>
</person-group>. <article-title>Protease-Activated Receptor 2 Agonist as Adjuvant: Augmenting Development of Protective Memory CD8 T Cell Responses Induced by Influenza Virosomes</article-title>. <source>J Immunol</source> (<year>2019</year>) <volume>203</volume>(<issue>2</issue>):<page-range>441&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1800915</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname> <given-names>AY</given-names>
</name>
<name>
<surname>Mann</surname> <given-names>TS</given-names>
</name>
<name>
<surname>McFawn</surname> <given-names>PK</given-names>
</name>
<name>
<surname>Han</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Henry</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Investigating the Role of MRGPRC11 and Capsaicin-Sensitive Afferent Nerves in the Anti-Influenza Effects Exerted by SLIGRL-Amide in Murine Airways</article-title>. <source>Respir Res</source> (<year>2016</year>) <volume>17</volume>(<issue>1</issue>):<fpage>62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12931-016-0378-8</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feld</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shpacovitch</surname> <given-names>V</given-names>
</name>
<name>
<surname>Ehrhardt</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fastrich</surname> <given-names>M</given-names>
</name>
<name>
<surname>Goerge</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ludwig</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Proteinase-Activated Receptor-2 Agonist Activates Anti-Influenza Mechanisms and Modulates IFNgamma-Induced Antiviral Pathways in Human Neutrophils</article-title>. <source>BioMed Res Int</source> (<year>2013</year>) <volume>2013</volume>:<fpage>879080</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2013/879080</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feld</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shpacovitch</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Ehrhardt</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kerkhoff</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hollenberg</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Vergnolle</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Agonists of Proteinase-Activated Receptor-2 Enhance IFN-Gamma-Inducible Effects on Human Monocytes: Role in Influenza A Infection</article-title>. <source>J&#xa0;Immunol</source> (<year>2008</year>) <volume>180</volume>(<issue>10</issue>):<page-range>6903&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.180.10.6903</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betts</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Mann</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Henry</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Inhibitory Influence of the Hexapeptidic Sequence SLIGRL on Influenza A Virus Infection in Mice</article-title>. <source>J Pharmacol Exp Ther</source> (<year>2012</year>) <volume>343</volume>(<issue>3</issue>):<page-range>725&#x2013;35</page-range>. doi: <pub-id pub-id-type="doi">10.1124/jpet.112.196485</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Goffic</surname> <given-names>R</given-names>
</name>
<name>
<surname>Balloy</surname> <given-names>V</given-names>
</name>
<name>
<surname>Lagranderie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Alexopoulou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Escriou</surname> <given-names>N</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Detrimental Contribution of the Toll-Like Receptor (TLR)3 to Influenza A Virus-Induced Acute Pneumonia</article-title>. <source>PloS Pathog</source> (<year>2006</year>) <volume>2</volume>(<issue>6</issue>):<fpage>e53</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.0020053</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bandara</surname> <given-names>M</given-names>
</name>
<name>
<surname>MacNaughton</surname> <given-names>WK</given-names>
</name>
</person-group>. <article-title>Protease-Activated Receptor-2 Activation Enhances Epithelial Wound Healing <italic>via</italic> Epidermal Growth Factor Receptor</article-title>. <source>Tissue Barriers</source> (<year>2021</year>) <fpage>1968763</fpage>. doi: <pub-id pub-id-type="doi">10.1080/21688370.2021.1968763</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Stacey</surname> <given-names>HD</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Mullarkey</surname> <given-names>CE</given-names>
</name>
</person-group>. <article-title>Neutrophils and Influenza: A Thin Line Between Helpful and Harmful</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>6</issue>):<elocation-id>597</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9060597</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Yano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kido</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Effects of Inhibitors of Toll-Like Receptors, Protease-Activated Receptor-2 Signalings and Trypsin on Influenza A Virus Replication and Upregulation of Cellular Factors in Cardiomyocytes</article-title>. <source>J Med Invest JMI</source> (<year>2011</year>) <volume>58</volume>(<issue>1-2</issue>):<fpage>19</fpage>&#x2013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.2152/jmi.58.19</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramaniam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ogoti</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hernandez</surname> <given-names>I</given-names>
</name>
<name>
<surname>Zogg</surname> <given-names>M</given-names>
</name>
<name>
<surname>Botros</surname> <given-names>F</given-names>
</name>
<name>
<surname>Burns</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>A Thrombin-PAR1/2 Feedback Loop Amplifies Thromboinflammatory Endothelial Responses to the Viral RNA Analogue Poly(I:C)</article-title>. <source>Blood Adv</source> (<year>2021</year>) <volume>5</volume>(<issue>13</issue>):<page-range>2760&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1182/bloodadvances.2021004360</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homma</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bhushan</surname> <given-names>B</given-names>
</name>
<name>
<surname>Norton</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Suh</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Carter</surname> <given-names>RG</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of Aspergillus Fumigatus in Triggering Protease-Activated Receptor-2 in Airway Epithelial Cells and Skewing the Cells Toward a T-Helper 2 Bias</article-title>. <source>Am J Respir Cell Mol Biol</source> (<year>2016</year>) <volume>54</volume>(<issue>1</issue>):<fpage>60</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1165/rcmb.2015-0062OC</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rallabhandi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nhu</surname> <given-names>QM</given-names>
</name>
<name>
<surname>Toshchakov</surname> <given-names>VY</given-names>
</name>
<name>
<surname>Piao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Medvedev</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Hollenberg</surname> <given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>Analysis of Proteinase-Activated Receptor 2 and TLR4 Signal Transduction: A Novel Paradigm for Receptor Cooperativity</article-title>. <source>J Biol Chem</source> (<year>2008</year>) <volume>283</volume>(<issue>36</issue>):<page-range>24314&#x2013;25</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M804800200</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname> <given-names>M</given-names>
</name>
<name>
<surname>Flick</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>GS</given-names>
</name>
</person-group>. <article-title>Modulation of the Nuclear Factor Kappa B Pathway by Shp-2 Tyrosine Phosphatase in Mediating the Induction of Interleukin (IL)-6 by IL-1 or Tumor Necrosis Factor</article-title>. <source>J Exp Med</source> (<year>2001</year>) <volume>193</volume>(<issue>1</issue>):<page-range>101&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.193.1.101</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saban</surname> <given-names>R</given-names>
</name>
<name>
<surname>D'Andrea</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Andrade-Gordon</surname> <given-names>P</given-names>
</name>
<name>
<surname>Derian</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Dozmorov</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ihnat</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Mandatory Role of Proteinase-Activated Receptor 1 in Experimental Bladder Inflammation</article-title>. <source>BMC Physiol</source> (<year>2007</year>) <volume>7</volume>:<fpage>4</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1472-6793-7-4</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGuire</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Rosner</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ananieva</surname> <given-names>O</given-names>
</name>
<name>
<surname>Ross</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Elcombe</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Naqvi</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Beta Interferon Production Is Regulated by P38 Mitogen-Activated Protein Kinase in Macrophages <italic>via</italic> Both MSK1/2- and Tristetraprolin-Dependent Pathways</article-title>. <source>Mol Cell Biol</source> (<year>2017</year>) <volume>37</volume>(<issue>1</issue>):<page-range>e00454&#x2013;16</page-range>. doi: <pub-id pub-id-type="doi">10.1128/MCB.00454-16</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname> <given-names>S</given-names>
</name>
<name>
<surname>Greer</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hooper</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zijlstra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>B</given-names>
</name>
<name>
<surname>Quigley</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The Membrane-Anchored Serine Protease, TMPRSS2, Activates PAR-2 in Prostate Cancer Cells</article-title>. <source>Biochem J</source> (<year>2005</year>) <volume>388</volume>(<issue>Pt 3</issue>):<page-range>967&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1042/BJ20041066</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bardou</surname> <given-names>O</given-names>
</name>
<name>
<surname>Menou</surname> <given-names>A</given-names>
</name>
<name>
<surname>Francois</surname> <given-names>C</given-names>
</name>
<name>
<surname>Duitman</surname> <given-names>JW</given-names>
</name>
<name>
<surname>von der Thusen</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Borie</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Membrane-Anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2016</year>) <volume>193</volume>(<issue>8</issue>):<page-range>847&#x2013;60</page-range>. doi: <pub-id pub-id-type="doi">10.1164/rccm.201502-0299OC</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yasuoka</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tsutsumi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hajime</surname> <given-names>M</given-names>
</name>
<name>
<surname>Takeuchi</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Human Airway Trypsin-Like Protease Enhances Interleukin-8 Synthesis in Bronchial Epithelial Cells by Activating Protease-Activated Receptor 2</article-title>. <source>Arch Biochem biophysics</source> (<year>2019</year>) <volume>664</volume>:<page-range>167&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.abb.2019.01.019</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwata-Yoshikawa</surname> <given-names>N</given-names>
</name>
<name>
<surname>Okamura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Shimizu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hasegawa</surname> <given-names>H</given-names>
</name>
<name>
<surname>Takeda</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nagata</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models After Coronavirus Infection</article-title>. <source>J Virol</source> (<year>2019</year>) <volume>93</volume>(<issue>6</issue>):<page-range>e01815&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01815-18</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>YP</given-names>
</name>
<name>
<surname>Kido</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Ectopic Trypsin in the Myocardium Promotes Dilated Cardiomyopathy After Influenza A Virus Infection</article-title>. <source>Am J Physiol Heart Circulatory Physiol</source> (<year>2014</year>) <volume>307</volume>(<issue>6</issue>):<page-range>H922&#x2013;32</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajpheart.00076.2014</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Yamada</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chida</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Up-Regulation of Ectopic Trypsins in the Myocardium by Influenza A Virus Infection Triggers Acute Myocarditis</article-title>. <source>Cardiovasc Res</source> (<year>2011</year>) <volume>89</volume>(<issue>3</issue>):<fpage>595</fpage>&#x2013;<lpage>603</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvq358</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaulieu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gravel</surname> <given-names>E</given-names>
</name>
<name>
<surname>Cloutier</surname> <given-names>A</given-names>
</name>
<name>
<surname>Marois</surname> <given-names>I</given-names>
</name>
<name>
<surname>Colombo</surname> <given-names>E</given-names>
</name>
<name>
<surname>Desilets</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Matriptase Proteolytically Activates Influenza Virus and Promotes Multicycle Replication in the Human Airway Epithelium</article-title>. <source>J Virol</source> (<year>2013</year>) <volume>87</volume>(<issue>8</issue>):<page-range>4237&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.03005-12</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tarnow</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mayoli-Nussle</surname> <given-names>D</given-names>
</name>
<name>
<surname>Schilling</surname> <given-names>E</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hammami</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Matriptase, HAT, and TMPRSS2 Activate the Hemagglutinin of H9N2 Influenza A Viruses</article-title>. <source>J Virol</source> (<year>2013</year>) <volume>87</volume>(<issue>3</issue>):<page-range>1811&#x2013;20</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02320-12</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ovcharenko</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Zhirnov</surname> <given-names>OP</given-names>
</name>
</person-group>. <article-title>Aprotinin Aerosol Treatment of Influenza and Paramyxovirus Bronchopneumonia of Mice</article-title>. <source>Antiviral Res</source> (<year>1994</year>) <volume>23</volume>(<issue>2</issue>):<page-range>107&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0166-3542(94)90038-8</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Park</surname> <given-names>KY</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>JS</given-names>
</name>
</person-group>. <article-title>Evaluation of Anti-Influenza Effects of Camostat in Mice Infected With Non-Adapted Human Influenza Viruses</article-title>. <source>Arch Virol</source> (<year>1996</year>) <volume>141</volume>(<issue>10</issue>):<page-range>1979&#x2013;89</page-range>. doi: <pub-id pub-id-type="doi">10.1007/BF01718208</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>W</given-names>
</name>
<name>
<surname>Chi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Development and Effects of Influenza Antiviral Drugs</article-title>. <source>Molecules</source> (<year>2021</year>) <volume>26</volume>(<issue>4</issue>):<elocation-id>810</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/molecules26040810</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrier</surname> <given-names>O</given-names>
</name>
<name>
<surname>Slama-Schwok</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means</article-title>. <source>Adv Exp Med Biol</source> (<year>2021</year>) <volume>1322</volume>:<fpage>195</fpage>&#x2013;<lpage>218</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-981-16-0267-2_8</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhuang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Pulmonary C Fibers Modulate MMP-12 Production <italic>via</italic> PAR2 and Are Involved in the Long-Term Airway Inflammation and Airway Hyperresponsiveness Induced by Respiratory Syncytial Virus Infection</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>90</volume>(<issue>5</issue>):<page-range>2536&#x2013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02534-15</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramaniam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ruf</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bosmann</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Advocacy of Targeting Protease-Activated Receptors in Severe Coronavirus Disease 2019</article-title>. <source>Br J Pharmacol</source> (<year>2021</year>). doi: <pub-id pub-id-type="doi">10.1111/bph.15587</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Bailo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Reihill</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Crilly</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Litherland</surname> <given-names>GJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Trypsin-Like Proteases and Their Role in Muco-Obstructive Lung Diseases</article-title>. <source>Int J Mol Sci</source> (<year>2021</year>) <volume>22</volume>(<issue>11</issue>):<elocation-id>5817</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/ijms22115817</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Jang</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Bouhaddou</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Obernier</surname> <given-names>K</given-names>
</name>
<name>
<surname>White</surname> <given-names>KM</given-names>
</name>
<etal/>
</person-group>. <article-title>A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing</article-title>. <source>Nature</source> (<year>2020</year>) <volume>583</volume>(<issue>7816</issue>):<page-range>459&#x2013;68</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>